SecBot SecBot
S-3 ·Filed Nov 12, 2026

EQ

Equillium, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed9d 14h ago SEC0001193125-26-458652
Shelf registration (potential dilution)
Actionable Insight • Neutral

The S-3 enables selling stockholders to sell shares into the market, creating potential overhang. Monitor trading volumes and any 424 prospectus supplements for actual sales. The company's cash position of $53.3M provides runway into 2029 per the prior 8-K summary.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

EQ drug pipeline →

EQ504

● Neutral Named in this S-3
Impact
Phase
Phase 1
Time to market
Unknown — the drug is in Phase 1 healthy-volunteer testing. If successful through Phase 2 and Phase 3, potential approval would be several years away (likely 2029-2031 at the earliest).
Next catalyst
None dated

What to watchThe next hard catalyst is topline Phase 1 proof-of-mechanism data in Q2 2027 (~6 months from now). Positive data showing AhR target engagement and a clean safety profile in healthy volunteers would validate the mechanism and support advancement into a Phase 2 proof-of-concept study in ulcerative colitis patients in H2 2027. Negative safety signals or failure to demonstrate target engagement would severely damage the thesis for a company now entirely dependent on EQ504 after its prior lead failed Phase 3.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.29
T+0 close · Nov 12, 2026 · via day close
Latest settled
−17.83%
T+5 · $1.06
Vs SPY
−9.27%
α at T+5
Next horizon
T+20
in 22d
  1. T+0 · Nov 13 $1.29entry
  2. T+1 · 6d ago −10.85%α −8.94% · $1.15
  3. T+5 · 2d ago −17.83%α −9.27% · $1.06
  4. T+20 · in 22d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Equillium filed an S-3 registration statement to register 35,087,717 shares of common stock for resale by selling stockholders who purchased shares and pre-funded warrants in a private placement that closed on October 26, 2026. The company will not receive any proceeds from the resale. The filing is a contractual obligation under a Registration Rights Agreement, not a new capital raise.

Key Facts

  • S-3 registers 35,087,717 shares for resale by selling stockholders, including 20,130,457 shares issuable upon exercise of pre-funded warrants
  • Shares were sold in a private placement at $0.57 per share (common) and $0.5699 per warrant, with aggregate gross proceeds of approximately $50.0 million
  • The company will not receive any proceeds from the resale under this prospectus
  • Filing is required under a Registration Rights Agreement dated August 12, 2025
  • As of September 30, 2026, the company had $53.3 million in cash and cash equivalents

Financial Impact

Up to 35.1M shares registered for resale, representing approximately 45% of the 78.4M shares outstanding as of October 30, 2026. The maximum aggregate offering price is estimated at $47.0M based on a reference price of $1.34 per share.

dilution

Risk Factors

  • Potential selling pressure from up to 35.1M shares being registered for resale
  • Pre-funded warrants with a nominal exercise price of $0.0001 could be exercised and sold at any time

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001193125-26-458652
Document: d934327dexfilingfees.htm0001193125-26-458652
Document: d934327dex51.htm0001193125-26-458652
Document: d934327dex231.htm0001193125-26-458652
Document: d934327dex232.htm0001193125-26-458652
Document: 0001193125-26-458652-index-headers.html0001193125-26-458652
Document: 0001193125-26-458652-index.html0001193125-26-458652
Document: 0001193125-26-458652.txt0001193125-26-458652

Track record

20 reports on EQ

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +20.40% at T+60 after the Jun 5, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 20, 20262d ago EFFECT Neutral 4/10 Entry $1.12 Now $1.06 −5.36% settles Nov 23
  2. Nov 16, 20265d ago SC 13G/A Neutral 3/10 Entry $1.21 to $1.10 Now $1.06 −12.40% ▼ −9.09% −8.79% vs SPY
  3. Nov 13, 20268d ago SC 13G/A Neutral 2/10 Entry $1.15 to $1.21 Now $1.06 −7.83% ▲ +5.22% +6.23% vs SPY
  4. Nov 12, 20269d ago S-3 Neutral 4/10 Viewing Entry $1.29 to $1.15 Now $1.06 −17.83% ▼ −10.85% −8.94% vs SPY
  5. Nov 12, 20269d ago 8-K Neutral 5/10 Entry $1.29 to $1.15 Now $1.06 −17.83% ▼ −10.85% −8.94% vs SPY
  6. Nov 12, 20269d ago SC 13G/A Neutral 2/10 Entry $1.32 to $1.29 Now $1.06 −19.70% ▼ −2.27% −1.91% vs SPY
  7. Nov 4, 202617d ago SC 13G/A Neutral 2/10 Entry $1.40 to $1.33 Now $1.06 −24.29% ▼ −5.00% −0.59% vs SPY
  8. Oct 26, 202626d ago 8-K Bearish 6/10 Entry $1.36 to $1.42 Now $1.06 +22.06% ▼ −4.41% −4.07% vs SPY
  9. Oct 26, 202626d ago Press Release Neutral 4/10 Entry $1.25 to $1.36 Now $1.06 −15.20% ▲ +8.80% +8.24% vs SPY
  10. Oct 5, 20266w ago 8-K Neutral 3/10 Entry $1.42 to $1.39 Now $1.06 −25.35% ▼ −2.11% −1.87% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens Mon (26h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026